Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?

Abstract

Two human group A rotavirus (RVA) vaccines are available and highly effective in preventing severe gastroenteritis caused by all commonly circulating human RVA genotypes. The effect of universal mass vaccination on the RVA genotype distribution is discussed based on the knowledge of complete RVA genotype constellations, data from clinical efficacy trials and effectiveness studies, and genotype surveillance data from countries with universal mass vaccination programs. The theoretically predicted relative enrichment of RVA strains with the G2P[4] DS-1-like genotype constellation in regions with high coverage by Rotarix(®) (GlaxoSmithKline Biologicals, Rixensart, Belgium) seems to become apparent. A G3P[8] genotype increase, which was noted in several regions with a high coverage of RotaTeq(®) (Merck and Co., Inc., NJ, USA), is more difficult to explain based on the theoretical considerations.

• Authors: Jelle Matthijnssens, Osamu Nakagomi, Carl D Kirkwood, Max Ciarlet, Ulrich Desselberger, Marc Van Ranst
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 11 Issue 11 Pg. 1347-54 (Nov 2012) ISSN: 1744-8395 [Electronic] England
• PMID: 23249234 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Rotavirus Vaccines

Topics

• Genotype
• Humans
• Mass Vaccination (methods)
• Molecular Epidemiology
• Rotavirus (classification, genetics, immunology, isolation & purification)
• Rotavirus Infections (epidemiology, prevention & control, virology)
• Rotavirus Vaccines (administration & dosage, immunology)
• Selection, Genetic